Abstract
We evaluated depression-related health care resource utilization and antidepressant prescription medication utilization among commercially insured men in the United States who underwent inflatable penile prosthesis (IPP) implantation between January 1, 2007 and December 31, 2020, and who received a depression diagnosis in the year preceding the IPP procedure. A total of 11,177 patients received an IPP during the index period, 808 of whom were diagnosed with depression. A statistically significant reduction in overall depression-related health care visits occurred from pre- to post-IPP, decreasing from 4.9 to 3.8,
< .001. In addition, there was a significant reduction in depression-related inpatient visits (0.07 vs. 0.03,
= .02) and office visits (4.25 vs. 3.29,
< .001) from pre- to post-IPP. Of the 678 men who received an antidepressant medication within 1 year prior to their IPP date, 15% stopped antidepressant medication use entirely post-IPP. Among patients with continued antidepressant medication use post-IPP (
= 574), there was a significant decrease in the number of prescriptions (7.55 vs. 8.09,
< .0001) and refills (7.52 vs. 8.11,
= .0015), with a higher likelihood of discontinuation (17.6% vs. 10.5%,
< .0001) and a lower proportion of days covered (0.79 vs. 0.83,
= .0004) post-IPP compared with pre-IPP. In conclusion, IPP was associated with reduced depression-related health care utilization and antidepressant medication use among recipients. This suggests potential mental health benefits for IPP recipients beyond restoration of erectile function. Comprehensive insurance coverage for IPP, especially for men with depression, may be beneficial to both patients and insurers.
